Limits...
Low expression of PKC α and high expression of KRAS predict poor prognosis in patients with colorectal cancer

View Article: PubMed Central - PubMed

ABSTRACT

The current study aimed to determine the association between protein kinase Cα (PKCα) and Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and the response to folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX regimen) in patients with colorectal cancer (CRC). The protein levels of PKCα and KRAS were analyzed by immunohistochemistry in tissue samples from patients with CRC and in non-cancerous tissues, including 152 cases of colorectal adenocarcinoma, 30 cases of colorectal adenoma and 20 normal colonic mucosa samples. The association between PKCα and KRAS expression and clinicopathological features was analyzed. The rates of positive PKCα protein expression in patients with poorly, moderately and well-differentiated adenocarcinoma were 16.7% (6/36), 40.0% (24/60), and 57.1% (32/56), respectively (P<0.013). The rate of positive KRAS expression in CRC patients was significantly higher than in patients with colon adenoma and normal colon mucosa (P<0.001). Expression levels of KRAS were associated with the degree of differentiation of CRC (P<0.001). Expression of PKCα was negatively correlated with KRAS expression in CRC tissues. The mean progression-free survival (PFS) times in patients with high and low expression of PKCα were 43.9 and 38.8 months, respectively (P<0.001). The mean PFS times were 38.5 and 45.5 months in patients with high and low expression of KRAS, respectively (P=0.001). In conclusion, low PKCα and high KRAS expression predicted relatively poor prognosis in patients with CRC.

No MeSH data available.


Related in: MedlinePlus

Survival times in different groups of patients, based on PKCα and KRAS expression. (A) PFS according to PKCα expression; (B) OS according to PKCα expression; (C) PFS according to KRAS expression; (D) OS according to KRAS expression. PKCα, protein kinase Cα; KRAS, Kirsten rat sarcoma viral oncogene homolog; PFS, progression-free survival; OS, overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998155&req=5

f2-ol-0-0-4845: Survival times in different groups of patients, based on PKCα and KRAS expression. (A) PFS according to PKCα expression; (B) OS according to PKCα expression; (C) PFS according to KRAS expression; (D) OS according to KRAS expression. PKCα, protein kinase Cα; KRAS, Kirsten rat sarcoma viral oncogene homolog; PFS, progression-free survival; OS, overall survival.

Mentions: A Cox multivariate survival analysis indicated that PKCα expression (P=0.003), KRAS expression (P=0.001) and Dukes' stage (P=0.011) were independent factors for predicting the prognosis of CRC patients (Table III). Kaplan-Meier curves and the log-rank test were used to analyze survival of patients. The mean durations of PFS were 43.9 and 38.8 months in the PKCα high-expression group and low-expression groups, respectively (P<0.001; Fig. 2A). The mean OS times were 76.0 and 65.9 months in the PKCα high- and low-expression groups, respectively (P<0.001; Fig. 2B). The mean durations of PFS were 38.5 and 45.5 months in the KRAS high- and low-expression groups, respectively (P=0.001; Fig. 2C). The mean durations of OS were 65.2 and 79.0 months in the KRAS high- and low-expression groups, respectively (P<0.001; Fig. 2D).


Low expression of PKC α and high expression of KRAS predict poor prognosis in patients with colorectal cancer
Survival times in different groups of patients, based on PKCα and KRAS expression. (A) PFS according to PKCα expression; (B) OS according to PKCα expression; (C) PFS according to KRAS expression; (D) OS according to KRAS expression. PKCα, protein kinase Cα; KRAS, Kirsten rat sarcoma viral oncogene homolog; PFS, progression-free survival; OS, overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998155&req=5

f2-ol-0-0-4845: Survival times in different groups of patients, based on PKCα and KRAS expression. (A) PFS according to PKCα expression; (B) OS according to PKCα expression; (C) PFS according to KRAS expression; (D) OS according to KRAS expression. PKCα, protein kinase Cα; KRAS, Kirsten rat sarcoma viral oncogene homolog; PFS, progression-free survival; OS, overall survival.
Mentions: A Cox multivariate survival analysis indicated that PKCα expression (P=0.003), KRAS expression (P=0.001) and Dukes' stage (P=0.011) were independent factors for predicting the prognosis of CRC patients (Table III). Kaplan-Meier curves and the log-rank test were used to analyze survival of patients. The mean durations of PFS were 43.9 and 38.8 months in the PKCα high-expression group and low-expression groups, respectively (P<0.001; Fig. 2A). The mean OS times were 76.0 and 65.9 months in the PKCα high- and low-expression groups, respectively (P<0.001; Fig. 2B). The mean durations of PFS were 38.5 and 45.5 months in the KRAS high- and low-expression groups, respectively (P=0.001; Fig. 2C). The mean durations of OS were 65.2 and 79.0 months in the KRAS high- and low-expression groups, respectively (P<0.001; Fig. 2D).

View Article: PubMed Central - PubMed

ABSTRACT

The current study aimed to determine the association between protein kinase C&alpha; (PKC&alpha;) and Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and the response to folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX regimen) in patients with colorectal cancer (CRC). The protein levels of PKC&alpha; and KRAS were analyzed by immunohistochemistry in tissue samples from patients with CRC and in non-cancerous tissues, including 152 cases of colorectal adenocarcinoma, 30 cases of colorectal adenoma and 20 normal colonic mucosa samples. The association between PKC&alpha; and KRAS expression and clinicopathological features was analyzed. The rates of positive PKC&alpha; protein expression in patients with poorly, moderately and well-differentiated adenocarcinoma were 16.7% (6/36), 40.0% (24/60), and 57.1% (32/56), respectively (P&lt;0.013). The rate of positive KRAS expression in CRC patients was significantly higher than in patients with colon adenoma and normal colon mucosa (P&lt;0.001). Expression levels of KRAS were associated with the degree of differentiation of CRC (P&lt;0.001). Expression of PKC&alpha; was negatively correlated with KRAS expression in CRC tissues. The mean progression-free survival (PFS) times in patients with high and low expression of PKC&alpha; were 43.9 and 38.8 months, respectively (P&lt;0.001). The mean PFS times were 38.5 and 45.5 months in patients with high and low expression of KRAS, respectively (P=0.001). In conclusion, low PKC&alpha; and high KRAS expression predicted relatively poor prognosis in patients with CRC.

No MeSH data available.


Related in: MedlinePlus